Screener
ImmunityBio, Inc. IBRX Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Principal payments on premium financing | (868) | — |
| Proceeds from borrowings | 61 | — |
| Principal payments of finance leases | (13) | — |
| Net cash provided by (used in) financing activities | 223,926 | (982) |
| Effect of exchange rate changes on cash and cash equivalents, and restricted cash | 122 | (10) |
| Net change in cash and cash equivalents, and restricted cash | 117,039 | (82,768) |
| Cash and cash equivalents, and restricted cash, beginning of period | 89,431 | 143,912 |
| Cash and cash equivalents, and restricted cash, end of period | $206,470 | $61,144 |
ITEM 1. FINANCIAL STATEMENTS.
FAQ
- What is ImmunityBio, Inc.'s financing cash flow?
- ImmunityBio, Inc. (IBRX) reported financing cash flow of $223.93M in Q1 2026.
- How has ImmunityBio, Inc.'s financing cash flow changed year-over-year?
- ImmunityBio, Inc.'s financing cash flow increased by 22903.1% year-over-year, from -$982K to $223.93M.
- What is the long-term trend for ImmunityBio, Inc.'s financing cash flow?
- Over 4 years (2021 to 2025), ImmunityBio, Inc.'s financing cash flow has grown at a -5.7% compound annual growth rate (CAGR), from $505.44M to $400.24M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about ImmunityBio, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude